The Novo Nordisk Foundation's $860M investment in BII signals strong support for early-stage biotechs. The venture's AI-driven drug resistance prediction aligns with BII's deep tech focus, though the founder's sole-founder status and pre-incorporation stage may require a strong co-founder or team plan to meet BII's typical criteria.